Osaka University Venture Capital was among the investors in a series D round for Kyorin University-founded cancer treatment developer J-Pharma.
J-Pharma, a Japan-based drug development spinout of Kyorin University, has raised ¥1.8bn ($16.3m) in a series D round involving university venturing unit Osaka University Venture Capital.
Spera Pharma, a chemistry, manufacturing and controls subsidiary of drug and medical supplies producer Iwaki Group, also backed the round alongside Mizuho Capital and Mitsubishi UFJ Capital, respective VC arms of financial services firms Mizuho Bank and financial services firm Mitsubishi UFJ Financial Group.
Drug manufacturer Ohara Pharmaceutical also contributed alongside research services provider KNC Laboratories and Iwagin Jigyo Souzou Capital, an affiliate of regional banking firm Bank of Iwate, in addition to Sansei Capital, part of insurer Taiji Life, life sciences personnel recruitment firm SRD Holdings and specialist materials firm Kisco.
The deal was rounded off by biomedicine-focused venture fund Newton Biocapital I, QB Capital, MBL Venture Capital, Nippon Venture Capital and KSP Corporation.
Founded in 2005, J-Pharma has assembled…
